N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 24 samples: 18 distinct titles, 2 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE249750_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1050279 and SRA study SRP476692. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 24 sample titles: 18 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7963612 MeRIP C4-2B Rep 1 Input
- GSM7963613 MeRIP C4-2B Rep 2 Input
- GSM7963614 MeRIP C4-2B Rep 3 Input
- GSM7963615 MeRIP C4-2B Rep 4 Input
- GSM7963616 MeRIP C4-2B Rep 1 RIP
- GSM7963617 MeRIP C4-2B Rep 2 RIP
- GSM7963618 MeRIP C4-2B Rep 3 RIP
- GSM7963619 MeRIP C4-2B Rep 4 RIP
- GSM7963620 MeRIP (C4-2B dataset) T24R2 Rep 1 Input
- GSM7963621 MeRIP (C4-2B dataset) T24R2 Rep 2 Input
- GSM7963622 MeRIP (C4-2B dataset) T24R2 Rep 3 Input
- GSM7963623 MeRIP (C4-2B dataset) T24R2 Rep 4 Input
- GSM7963624 MeRIP (C4-2B dataset) T24R2 Rep 1 RIP (C4-2B dataset)
- GSM7963625 MeRIP (C4-2B dataset) T24R2 Rep 2 RIP (C4-2B dataset)
- GSM7963626 MeRIP (C4-2B dataset) T24R2 Rep 3 RIP (C4-2B dataset)
- GSM7963627 MeRIP (C4-2B dataset) T24R2 Rep 4 RIP (C4-2B dataset)
- GSM7963628 RNAseq C4-2B Rep1
- GSM7963629 RNAseq C4-2B Rep2
- GSM7963630 RNAseq C4-2B Rep3
- GSM7963631 RNAseq C4-2B Rep4
- GSM7963632 RNAseq MDVR Rep1
- GSM7963633 RNAseq MDVR Rep2
- GSM7963634 RNAseq MDVR Rep3
- GSM7963635 RNAseq MDVR Rep4
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares prostate
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
- GSE302818 SPEN is an androgen receptor dependent tumor suppressor and mediates hormonal therapy resistance in prostate cancer 38 samples shares resistance, prostate
- GSE255154 Epigenetic disruption of the RARgamma complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancer 139 samples shares enzalutamide, prostate
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.